Physician profile
Richard Stephens
NPI 1003858861
$935.57
in general payments reported to CMS, 2019-2025
21 companies · $19.17 in 2025
The $19.17 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $32.74 · 2021: $121 · 2022: $132 · 2023: $311 · 2024: $154 · 2025: $19.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $483.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $160.28 | 2023 | Myrisk |
| Astellas Pharma US INC | $109.93 | 2019-2023 | Veozah, Myrbetriq |
| Abbvie INC. | $98.71 | 2019-2022 | |
| Hologic Sales and Service, LLC | $89.03 | 2019-2024 | Aptima |
| Inspire Medical Systems, INC. | $82.94 | 2024 | Inspire |
| Boston Scientific Corporation | $58.92 | 2023 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $51.04 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.99 | 2022 | |
| Pfizer INC. | $41.81 | 2022 | |
| Exeltis, USA INC. | $34.38 | 2021-2024 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $19.17 | 2025 | |
| Glaxosmithkline, LLC. | $18.65 | 2023 | Trelegy Ellipta |
| Acella Pharmaceuticals, LLC | $16.82 | 2024 | NP Thyroid 60 |
| Covidien LP | $16.24 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.22 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $14.30 | 2021 | |
| Medtronic, INC. | $14.30 | 2024 | Interstim |
| Allergan, INC. | $12.50 | 2019 | |
| Esperion Therapeutics, INC. | $11.77 | 2022 | |
| Novo Nordisk INC | $11.43 | 2021 | |
| Merck Sharp & Dohme LLC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.